Source: Virtual Congress 2021 – Back to infection basics



Rating:

Share or cite this content

Citations should be made in the following way:
P. Clot (Chilly-Mazarin, France), C. Farenc (Montpellier, France), B. Suratt (Cambridge, United States of America), T. Krahnke (Frankfurt, Germany), A. Tardat (Montpellier, Germany), P. Florian (Frankfurt, Germany), R. Pomponio (Framingham, United States of America), N. Patel (Cambridge, United States of America), M. Wiekowski (Bridgewater, United States of America), Y. Lin (Bridgewater, United States of America), B. Terrier (Paris, France), H. Staudinger (Bridgewater, United States of America). Late Breaking Abstract - Immunomodulatory and clinical effects of RIPK1 inhibitor SAR443122 in patients with severe COVID-19. 2363

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Efficacy of DPP1 inhibition with brensocatib in subgroups of patients with bronchiectasis- the WILLOW study Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020 Late Breaking Abstract - Daily physical activity in patients with severe asthma and the effect of anti-IL5 therapy. Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Late Breaking Abstract - Treatment with ATYR1923 reduces biomarkers in COVID-19 pneumonia Source: Virtual Congress 2021 – Diagnosis and management of COVID-19 Year: 2021 Late Breaking Abstract - ND-L02-s0201 treatment leads to efficacy in preclinical IPF models Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Late Breaking Abstract - The efficacy of roflumilast in the treatment of COPD(stage B). Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Late Breaking Abstract - Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial. Source: International Congress 2017 – Interstitial lung diseases (ILDs): novel pathogenetic pathways Year: 2017 Late Breaking Abstract - 12-month lung clinical and functional consequences in patients with severe COVID-19 Source: Virtual Congress 2021 – Biological and functional markers of COVID-19 Year: 2021 Late Breaking Abstract - Anti-inflammatory and anti-fibrotic effect of novel, pan-PDE inhibitors in human bronchial epithelial cells Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020 Late Breaking Abstract - Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Late Breaking Abstract: Cathelicidin has direct anti-rhinoviral activity Source: Annual Congress 2010 - Cell biology and immunology of lung disease Year: 2010 Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy. Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Late Breaking Abstract - Promising results of the infliximab biosimilar Inflectra® in severe sarcoidosis patients Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Late Breaking Abstract: Activation of the WNT/β-catenin pathway attenuates experimental emphysema Source: Annual Congress 2010 - Novel cellular mechanisms in lung disease Year: 2010 Late Breaking Abstract - Effects of pulmonary rehabilitation on major symptoms of long COVID (post-COVID-19 syndrome): preliminary results Source: Virtual Congress 2021 – A multidisciplinary approach to pulmonary rehabilitation and management of chronic respiratory diseases Year: 2021 Late Breaking Abstract - Identification of patients with COPD who benefit from benralizumab Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019 Late Breaking Abstract - Cardiovascular adverse events of drugs targeting IL-5 in severe asthma: a pharmacovigilance study Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights Year: 2020 Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study Source: Virtual Congress 2020 – ALERT: Pneumothorax, cough, PAH, alveolar proteinosis Year: 2020 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Detection of clinical instability by eNose in COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018